Special Issue "New Developments in Radiotherapy"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 October 2018).
Interests: DNA damage response: PARP, ATR, CHK1, ATM, DNA-PK; Functional biomarkers of DNA repair
Special Issues and Collections in MDPI journals
Interests: radiation biology; proton beam therapy; DNA damage; DNA repair; base excision repair
More than half of all cancer patients receive radiotherapy as part of their treatment, and 40 % of all patients who are cured of cancer have received radiotherapy. Radiotherapy is also used for palliation and is one of the most cost-effective treatments for cancer. Recent years have seen several major developments in how radiotherapy is given with the use of image-guided high precision external beam radiation such as stereotactic radiotherapy (SBRT and SABR) hypofractionation, proton beam therapy as well as developments in the use of brachytherapy and targeted radionuclides. Moreover several novel combinations beyond the conventional cytotoxic radiosensitisers using molecularly-targeted agents directed at the DNA damage response, hypoxia, metabolism and angiogenesis, as well as immunotherapy agents, are under investigation. These developments have been supported by preclinical investigations that have benefitted from improvements in small animal imaging and irradiation (SARRP). The aim of this Special Issue is to provide an up-to-date overview of these new developments.
Prof. Dr. Nicola Curtin
Dr. Jason Parsons
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.